Topics:

Full FDA Approval for Camptosar

Full FDA Approval for Camptosar

ROCKVILLE, Md—The FDA has granted full approval to Pharmacia & Upjohn’s Camptosar (irinotecan), based on survival data. Camptosar is indicated for use in patients with metastatic colorectal cancer whose disease has recurred or spread after treatment with the current standard chemotherapy. The agent received accelerated FDA approval in June 1996.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.